InSite Vision Incorporated (INSV) has reported that the US District Court for the District of New Jersey upheld all four of the patents protecting AzaSite, an azithromycin 1% ophthalmic solution, in a patent infringement lawsuit against ...
The US Patent and Trademark Office (USPTO) has granted an US patent to the InSite Vision’s DuraSite 2 next-generation enhanced drug delivery system, which will be valid up to 2029 for internal pipeline and partnering. Offering a ...
Tags: Drug Delivery System
InSite Vision has secured the new patent for its DuraSite 2 next-generation enhanced drug delivery system from the United States Patent and Trademark Office (USPTO). DuraSite 2's ability to significantly improve drug retention and ...
Tags: Insite Vision, Ophthalmic Drug
InSite Vision has again secured the development rights for zithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra, from Merck's subsidiary, Inspire Pharmaceuticals, in North America. According to the deal, a joint development ...
Tags: North America, InSite Vision, AzaSite Xtra
InSite Vision has launched a new DuraSite 2 drug delivery system, designed to deliver ophthalmic therapeutics. DuraSite 2, which is based on InSite DuraSite technology, incorporates cataract surgery drug, ketorolac, a non-steroidal ...
Tags: InSite, Ophthalmic Drug Delivery System, ophthalmic therapeutics
Ophthalmologic products provider, InSite Vision has started the patient enrollment for the first Phase 3 clinical trial of BromSite (ISV-303), which is used to reduce pain and inflammation post cataract surgery. The study will enroll ...
Tags: Insite Vision, BromSite Phase 3 Study, Ophthalmologic products